Clinical Trial Update: Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial [Phase 2]

View source ↗

Summary

Phase 2 trial update for a neoadjuvant intravesical therapy combining nadofaragene firadenovec with gemcitabine, cisplatin, and durvalumab in muscle-invasive bl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Durvalumab (durvalumab)
• Gemcitabine (Gemcitabine)
• Nadofaragene firadenovec (nadofaragene firadenovec)

Snippet

Sponsor: University of Washington | Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Status: NOT_YET_RECRUITING